Shire, Baxalta in late-stage talks on $32B tie-up: Bloomberg

Shire ($SHPG) is finally nearing the Baxalta ($BXLT) buyout it's long coveted, according to Bloomberg's sources. The two drugmakers are discussing a price between $46.50 and $48 per share, the news service reports, which would value the Illinois pharma at about $32 billion. A tie-up, Shire CEO Flemming Ornskov has said, would create a global rare-disease leader that can bring in $20 billion in sales by 2020. More from FiercePharma

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.